SB 266 creates a new, exclusive civil cause of action in Utah for claims involving exposure to ethylene oxide, a chemical used in the healthcare industry for sterilizing medical devices. The bill defines the healthcare industry broadly to include entities involved in the manufacturing, sale, distribution, sterilization, storage, and transportation of medical devices, and it sets out a specialized legal framework for these claims.
Under the bill, a person or business in the healthcare industry generally cannot be held liable for ethylene oxide exposure unless the plaintiff proves, by a preponderance of the evidence, that the defendant was not in substantial compliance with applicable federal ethylene oxide laws or standards, engaged in gross negligence or willful misconduct, and that the exposure was the direct and proximate cause of the plaintiff’s injury. The bill also imposes heightened pleading requirements, including particularized allegations of each element of the claim, specific damage calculations, and facts supporting any required state-of-mind allegation.
The bill further states that this new chapter is the exclusive remedy for ethylene oxide exposure actions and that it preempts and supersedes other Utah state laws related to recovery for personal injuries from actual, alleged, feared, or potential ethylene oxide exposure. It applies to pending cases and new cases filed on or after May 7, 2025, while expressly preserving workers’ compensation schemes and defenses.
The overall sentiment in the recorded votes appears favorable, with the bill advancing comfortably through both chambers. It received strong majority support in Senate and House floor votes, though not unanimously, suggesting some concern but not broad opposition. The lack of committee transcript material limits insight into detailed debate, but the vote pattern indicates the bill was generally supported as a targeted litigation reform.
The main points of contention likely center on the bill’s liability protections for healthcare-industry actors, its exclusive-remedy structure, and its preemption of other personal injury laws. Critics would likely view the measure as making it harder for injured plaintiffs to bring or prove claims, while supporters would likely argue it creates clarity, uniform standards, and protection for entities that use ethylene oxide in medically necessary sterilization processes.
The bill enacts new sections in Title 78B, Chapter 3, creating a specialized statutory cause of action for ethylene oxide exposure and displacing other state-law avenues for related personal injury claims. It narrows liability for healthcare-industry defendants, raises pleading and proof requirements, and preempts conflicting Utah laws, while leaving workers’ compensation law intact. The practical effect is to channel ethylene oxide exposure litigation into a single statutory framework and limit recovery unless plaintiffs can meet the bill’s heightened standards.
The bill appears to have been viewed positively by a majority of legislators, as reflected in favorable committee recommendations and strong floor passage in both the Senate and House. At the same time, the non-unanimous votes indicate that some lawmakers had reservations about the scope of the liability protections and the preemption of other remedies. Overall, the sentiment was supportive but not without some opposition.
The principal controversy is the balance between protecting healthcare-industry entities that use ethylene oxide for sterilization and preserving remedies for people alleging injury from exposure. Opponents are likely to object to the bill’s exclusive-cause-of-action language, its preemption of other personal injury laws, and the requirement that plaintiffs prove gross negligence or willful misconduct plus proximate causation. Supporters, by contrast, likely favor the bill’s uniform standards, narrowed liability, and heightened pleading rules as a way to reduce uncertain or expansive litigation.